Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer

Kalachand, Roshni D., O'Riain, Ciaran, Toomey, Sinead, Carr, Aoife, Timms, Kirsten M., O'Toole, Sharon, Madden, Stephen, Bates, Mark, O'Leary, John J., Gleeson, Noreen, O'Donnell, Dearbhaile, Grogan, Liam, Breathnach, Oscar, Farrelly, Angela, Stordal, Britta K. ORCID logoORCID: and Hennessy, Bryan T. (2020) Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstetrics & Gynecology Science, 63 (5) . pp. 643-654. ISSN 2287-8572 [Article] (doi:10.5468/ogs.20033)

PDF - Published version (with publisher's formatting)
Available under License Creative Commons Attribution-NonCommercial 4.0.

Download (472kB) | Preview


The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defects in tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with tumor BRCA1/2 mutations and BRCA1 methylation in women with OC.
We obtained 111 OC specimens from 2 university hospitals and assessed BRCA1/2 mutations and BRCA1 methylation in tumor DNA. The frequency and pattern of BRCA1/2 defects were examined. Associations between patient/disease characteristics and BRCA1/2 defects were ascertained (Fisher’s exact test). Platinum-free interval (PFI), progression-free survival (PFS), and overall survival (OS) based on the underlying BRCA1/2 defect were determined (Kaplan-Meier analysis [log-rank test]).
We observed a BRCA1/2 dysfunction rate of 40% (28/70) in high-grade serous tubal/ovarian cancer (HGSC), including 14.3% BRCA1 methylation (n=10), 7.1% BRCA1 mutation (n=5), and 18.6% BRCA2 mutation (n=13). Defects in BRCA1/2 genes were associated with stage III/IV HGSC (BRCA1 methylation: P=0.005 [stage III/IV] and P=0.004 [HGSC]; BRCA1/2 mutation: P=0.03 [stage III/IV] and P<0.001 [HGSC]). Patients with BRCA1/2-mutated cancers showed improved OS (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43–0.99; P=0.045) and a trend toward improved PFI (HR, 0.48; 95% CI, 0.22–1.06; P=0.07) and PFS (HR, 0.72; 95% CI, 0.51–1.03; P=0.07). No survival differences were observed between BRCA1-methylated and BRCA1/2 wild-type non-BRCA1-methylated cancers.
We observed a high tumor BRCA1/2 dysfunction rate in HGSC with a unique predominance of BRCA2 over BRCA1 mutations. While BRCA1/2 mutations conferred survival benefits in OC, no such association was observed with BRCA1 methylation.

Item Type: Article
Sustainable Development Goals:
Research Areas: A. > School of Science and Technology > Natural Sciences > Biomarkers for Cancer group
Item ID: 35366
Notes on copyright: Copyright © 2020 Korean Society of Obstetrics and Gynecology
Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Useful Links:
Depositing User: Britta Stordal
Date Deposited: 06 Jul 2022 15:03
Last Modified: 06 Jul 2022 15:03

Actions (login required)

View Item View Item


Activity Overview
6 month trend
6 month trend

Additional statistics are available via IRStats2.